Hussman Strategic Advisors Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Hussman Strategic Advisors Inc. bought a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 105,000 shares of the biopharmaceutical company's stock, valued at approximately $897,000. Hussman Strategic Advisors Inc. owned 0.07% of Ocular Therapeutix at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 1,015 shares during the period. Capital Performance Advisors LLP purchased a new stake in Ocular Therapeutix in the third quarter worth about $70,000. Palumbo Wealth Management LLC purchased a new stake in Ocular Therapeutix in the fourth quarter worth about $100,000. Creative Planning purchased a new stake in Ocular Therapeutix in the third quarter worth about $182,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Ocular Therapeutix by 64.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 29,989 shares of the biopharmaceutical company's stock worth $261,000 after acquiring an additional 11,793 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Donald Notman sold 6,301 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the transaction, the insider now owns 204,563 shares in the company, valued at $1,603,773.92. This represents a 2.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey S. Heier sold 2,948 shares of the company's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. This trade represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,368 shares of company stock valued at $162,801. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Stock Performance

OCUL stock opened at $7.25 on Friday. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -5.49 and a beta of 1.22. The firm has a 50-day simple moving average of $8.11 and a two-hundred day simple moving average of $8.95. Ocular Therapeutix, Inc. has a one year low of $4.06 and a one year high of $11.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $17.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.